Kodiak Sciences is a biotechnology business based in the US. Kodiak Sciences shares (KOD) are listed on the NASDAQ and all prices are listed in US Dollars. Kodiak Sciences employs 107 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.02 |
|---|---|
| 52-week range | $1.37 - $7.77 |
| 50-day moving average | $2.88 |
| 200-day moving average | $3.51 |
| Wall St. target price | $3.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-4.44 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.02 from 2024-07-24
| 1 week (2024-07-19) | 5.23% |
|---|---|
| 1 month (2024-06-26) | 31.88% |
| 3 months (2024-04-26) | -7.93% |
| 6 months (2024-01-26) | -39.36% |
| 1 year (2023-07-26) | -6.79% |
|---|---|
| 2 years (2022-07-26) | -67.87% |
| 3 years (2021-07-26) | 85.9 |
| 5 years (2019-07-26) | 12.7 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -28.92% |
| Return on equity TTM | -73.45% |
| Profit margin | 0% |
| Book value | $4.61 |
| Market Capitalization | $150.8 million |
TTM: trailing 12 months
We're not expecting Kodiak Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Kodiak Sciences's shares have ranged in value from as little as $1.37 up to $7.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kodiak Sciences's is 2.371. This would suggest that Kodiak Sciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kodiak Sciences Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.